Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with Remdesivir

15 Apr 2021

Abstract excerpt

Abstract The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global threat to human health. Using a multidisciplinary approach, we identified and validated the hepatitis C virus (HCV) protease inhibitor simeprevir as an especially promising repurposable drug for treating COVID-19. Simeprevir potently reduces SARS-CoV-2 viral load by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Hepatitis C virus research
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34075346
DOI: 10.1021/acscentsci.0c01186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simeprevir Potently Suppresses SARS-CoV‑2 Replication and Synergizes with RemdesivirPMID 34075346Read ↗

Simeprevir Potently Suppresses SARS-CoV‑2 Replication\nand Synergizes with RemdesivirSemantic proximity Read ↗

Hepatitis C Virus Drugs Simeprevir And Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV2 ReplicationSemantic proximity Read ↗

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In VitroSemantic proximity Read ↗

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read ↗

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic targetSemantic proximity Read ↗

Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymeraseSemantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity Read ↗

Potential Inhibitors Targeting RNA-Dependent RNA Polymerase Activity (NSP12) of SARS-CoV-2Semantic proximity Read ↗

Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesSemantic proximity Read ↗

Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.